- Home
- ZIP vs RGNX Comparison
ZIP vs RGNX Comparison
Compare ZIP & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIP
- RGNX
- Stock Information
- Founded
- ZIP 2010
- RGNX 2008
- Country
- ZIP United States
- RGNX United States
- Employees
- ZIP N/A
- RGNX N/A
- Industry
- ZIP Diversified Commercial Services
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZIP Consumer Discretionary
- RGNX Health Care
- Exchange
- ZIP Nasdaq
- RGNX Nasdaq
- Market Cap
- ZIP 427.4M
- RGNX 451.1M
- IPO Year
- ZIP 2021
- RGNX 2015
- Fundamental
- Price
- ZIP $5.06
- RGNX $9.28
- Analyst Decision
- ZIP Hold
- RGNX Strong Buy
- Analyst Count
- ZIP 4
- RGNX 8
- Target Price
- ZIP $4.75
- RGNX $28.50
- AVG Volume (30 Days)
- ZIP 1.2M
- RGNX 623.2K
- Earning Date
- ZIP 11-05-2025
- RGNX 11-05-2025
- Dividend Yield
- ZIP N/A
- RGNX N/A
- EPS Growth
- ZIP N/A
- RGNX N/A
- EPS
- ZIP N/A
- RGNX N/A
- Revenue
- ZIP $450,401,000.00
- RGNX $155,782,000.00
- Revenue This Year
- ZIP N/A
- RGNX $260.25
- Revenue Next Year
- ZIP $9.94
- RGNX N/A
- P/E Ratio
- ZIP N/A
- RGNX N/A
- Revenue Growth
- ZIP N/A
- RGNX 74.95
- 52 Week Low
- ZIP $3.35
- RGNX $5.04
- 52 Week High
- ZIP $11.25
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- ZIP 56.74
- RGNX 52.85
- Support Level
- ZIP $4.59
- RGNX $9.15
- Resistance Level
- ZIP $5.08
- RGNX $10.08
- Average True Range (ATR)
- ZIP 0.26
- RGNX 0.52
- MACD
- ZIP 0.00
- RGNX 0.03
- Stochastic Oscillator
- ZIP 60.51
- RGNX 44.06
About ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace. It connects millions of job seekers with companies of all sizes. It is a two-sided marketplace for work that simplifies the job market for both job seekers and employers. Unlike traditional online job sites, ZipRecruiter works like a matchmaker curating job opportunities for job seekers, and candidates for employers.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.